Screener
Beam Therapeutics BEAM Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 104,524 | 98,816 |
| General and administrative | 34,429 | 27,940 |
| Total operating expenses | 138,953 | 126,756 |
| Loss from operations | (107,215) | (119,286) |
| Other income (expense): | ||
| Change in fair value of derivative liabilities | 2,500 | 3,200 |
| Change in fair value of non-controlling equity investments | 16 | (2,081) |
| Change in fair value of contingent consideration liabilities | 514 | (27) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's operating income?
- Beam Therapeutics (BEAM) reported operating income of -$107.22M in Q1 2026.
- How has Beam Therapeutics's operating income changed year-over-year?
- Beam Therapeutics's operating income increased by 10.1% year-over-year, from -$119.29M to -$107.22M.
- What is the long-term trend for Beam Therapeutics's operating income?
- Over 3 years (2021 to 2025), Beam Therapeutics's operating income has grown at a -0.8% compound annual growth rate (CAGR), from -$392.47M to -$383.69M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Beam Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude